Gastrointestinal stromal tumor has been described in this insightful book. Till about 15 years ago, there was no mechanism to detect the origin of Gastrointestinal Stromal Tumor (GIST), and 30 years back, no one thought that GISTs derive from mesenchymal stem elements. Experiments in the past 10 years have stressed on the justification of imatinib mezylate therapy in GISTs and given an answer to why a secondary resistance originated during the kinase inhibitors therapy. The era of treatments for GISTs, focusing on the primary activating mutations in the KIT proto-oncogene has been tagged as the new indicator of special importance to the pathologist role in integrative unit that is accountable for curing diseased people with commonly used or metastatic GIST. The book portrays this message in a consolidative manner. Additionally, it imparts knowledge on the precise and case based information on current management of gastrointestinal and extragastrointestinal stromal tumors. This book will prove to be educational and worthy of the time of the students, and will be a good addition to clinical science dissemination, medical education, and further basic and clinical research.